Neurocrine Biosciences has posted initial results from a Phase IIb study of NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia. The treatment showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in as long as 12 weeks of continuous dosing. This is the second study reporting out this week that demonstrates the potential of NBI-98854 as a safe and highly effective therapy for tardive dyskinesia sufferers. Both of th...